

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Acting Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE

AGENDA

Date of Publication: November 9, 2016

Date and Time of Meeting: Thursday, December 8, 2016 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: Springs Preserve
Desert Living Center
333 S. Valley View Blvd
Las Vegas, NV 89107
Phone: (702) 822-7700
Please check with staff to verify room location

Webinar Registration: <https://catamaranrx.webex.com/catamaranrx/onstage/g.php?MTID=e73a77f1ec5b4620666829ee57f8cb0f9>

OR

www.webex.com, select “Join”, enter Meeting Number 749 819 716, your name and email and then select, “Join”.

A Password should not be necessary, but if asked, enter, “Medicaid”

Event Number: 749 819 716

Follow the instructions that appear on your screen to join the teleconference. Audio will be broadcast over the internet (VoIP).

*Nevada Department of Health and Human Services
Helping People -- It's Who We Are And What We Do*

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Tanya Benitez at: 775-684-3722 or email Tanya.Benitez@dhefp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to 5 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

AGENDA

1. Call to Order and Roll Call

2. Public Comment

3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from September 22, 2106
- b. Status Update by DHEFP
 - i. Public Comment

4. Established Drug Classes

- a. Musculoskeletal Agents: Anticancer Agents
 - i. Public Comment
 - ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
 - v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Hematological Agents: Anticoagulants – Oral
 - i. Public Comment
 - ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups

- iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
- v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

5. Established Drug Classes Being Reviewed Due to the Release of New Drugs

- a. Cardiovascular Agents: Antihypertensive Agents: Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
 - i. Public Comment
 - ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
 - v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- b. Psychotropic Agents: Anxiolytics, Sedatives, and Hypnotics
 - i. Public Comment
 - ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
 - v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- c. Otic Agents: Otic Antiinfectives – Otic Quinolones
 - i. Public Comment
 - ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
 - v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- d. Hormones and Hormone Modifiers: Antidiabetic Agents - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors
 - i. Public Comment

- ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
 - v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL
- e. Biologic Response Modifiers: Targeted Immunomodulators
- i. Public Comment
 - ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
 - v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

6. Proposed New Classes

- a. Functional Gastro-intestinal Disorder Drugs
 - i. Public Comment
 - ii. Drug Class Review Presentation – OptumRx
 - iii. **For Possible Action:** Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - iv. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by OptumRx and the Division of Health Care Financing and Policy
 - v. **For Possible Action:** Committee Discussion and Approval of Drugs for Inclusion on the PDL

7. Report by OptumRx on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions

8. Closing Discussion

- a. Public comments on any subject
- b. Date and location of the next meeting
- c. Adjournment

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been

allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

This notice and agenda have been posted at <http://dhcfp.nv.gov/> and notice.nv.gov/.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site <http://dhcfp.nv.gov/> Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Ellen Felsing at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at: ellen.felsing@dhcfp.nv.gov, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Ellen Felsing at (775) 684-3684.
